CA125, YKL-40, HE-4 and Mesothelin: a new serum biomarker combination in discrimination of benign and malign epithelial ovarian tumor

Deveci B., Serdar B. S., Kemik P. K., Keskin H., YILDIRIM N., ÖZDEMİR N., ...Daha Fazla

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.44, sa.4, ss.438-451, 2019 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 44 Sayı: 4
  • Basım Tarihi: 2019
  • Doi Numarası: 10.1515/tjb-2019-0038
  • Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.438-451
  • Anahtar Kelimeler: Epithelial ovarian cancer, CA125, HE4, Mesothelin, YKL-40, EPIDIDYMIS PROTEIN 4, CANCER, CARCINOMA, DIAGNOSIS, ALGORITHM, MARKER, WOMEN, RISK, TIME, SMRP
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective: Cancer Antigen 125 (CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) score are used for classification of ovarian masses (benign/malign) in preoperative stage. However, their discrimination capacity are considered insufficient, and greatly effected by histological subtype and menopausal status. This study aimed to investigate diagnostic performance of Human epididymis protein 4 (HE4), Y (tyrosine), K (lysine), and L (leucine)-40 (YKL-40), Mesothelin, Rho GDP dissociation inhibitor beta (LyGDI), CA125 or their combinations in discrimination of benign/malign ovarian diseases in preoperative stage.